Navigation Links
Cannabinoid in Medical News

Turned-off cannabinoid receptor turns on colorectal tumor growth

HOUSTON - New preclinical research shows that cannabinoid cell surface receptor CB1 plays a tumor-suppressing role in human colorectal cancer, scientists report in the Aug. 1 edition of the journal Cancer Research . CB1 is well-established for relieving pain and nausea, elevating mood and stim...

Milestone for cannabinoid MS study

The CUPID (Cannabinoid Use in Progressive Inflammatory brain Disease) study at the Peninsula Medical School in Plymouth has reached an important milestone with the news that the full cohort of 493 people with multiple sclerosis (MS) has been recruited to the study. CUPID is a clinical trial whi...

Synthetic Cannabinoid Could Improve Fertility in Smokers

A reproductive medicine expert from the University at Buffalo has demonstrated the capacity of a new compound that could enhance// the fertility of tobacco smokers, who have a deficient sperm count and sperm mobility. A synthetic chemical called AM-1346 was used to wash the sperm from male sm...

Pharmos Corporation Reports 2009 First Quarter Results

...ndpoint of adequate relief (n=141, p=0.033). The Company also has a proprietary technology platform focusing on discovery and development of synthetic cannabinoid compounds with a focus on CB2 receptor selective agonists. Various CB2-selective compounds from Pharmos' pipeline have completed preclinical studies t...

Pharmos Completes Private Placement - Raises $1.8 Million

...ndpoint of adequate relief (n=141, p=0.033). The Company also has a proprietary technology platform focusing on discovery and development of synthetic cannabinoid compounds with a focus on CB2 receptor selective agonists. Various CB2-selective compounds from Pharmos' pipeline have completed preclinical studies t...

Pharmos Corporation Announces Receipt of Nasdaq Delisting Determination

...ndpoint of adequate relief (n=141, p=0.033). The Company also has a proprietary technology platform focusing on discovery and development of synthetic cannabinoid compounds with a focus on CB2 receptor selective agonists. Various CB2-selective compounds from Pharmos' pipeline have completed preclinical studies t...

Pharmos Corporation Announces Modification to Dextofisopam Trial Size, Objectives Can Still Be Achieved

...ndpoint of adequate relief (n=141, p=0.033). The Company also has a proprietary technology platform focusing on discovery and development of synthetic cannabinoid compounds with a focus on CB2 receptor selective agonists. Various CB2-selective compounds from Pharmos' pipeline have completed preclinical studies t...

Marijuana use linked to increased risk of testicular cancer

... said. In future studies the researchers plan to measure the expression of cannabinoid receptors in both seminomatous and nonseminomatous tumor tissue from the ca...er variation in the genes for the receptors and other molecules involved in cannabinoid signaling influences the risk of testicular cancer. In the meantime, Schwa...

US Cancer Pain Market to Reach $5 Billion by 2018 - Cancer Patient Growth Drives Value

...t of the drugs recently approved in the world for the treatment of cancer pain are opiates. One exception is GW's dronabinol/cannabidiol (Sativex), a cannabinoid receptor agonist recently approved in Canada for the treatment of cancer pain. The US has not seen a recent approval, but BDSI's ONSOLIS has reached ...

Schizophrenia linked to dysfunction in molecular brain pathway activated by marijuana

...eneral Psychiatry , one of the JAMA/Archives journals. Expression of the cannabinoid 1 receptor (CB1R), the site of action of the main chemical ingredient of ma...ol (THC), the main psychoactive ingredient in marijuana, and the brains own cannabinoid chemical messengers." Dr. Lewis and his colleagues examined specimens of...
Cannabinoid in Medical Technology

Study of Cannabinoid Medicine for Pain Found Patients Got 'High,' but Effects Not Related to Pain Relief

HONOLULU, Jan. 28 /PRNewswire/ -- Researchers at Brigham and Women's Hospital found that patients taking cannabinoid medicines for pain may be getting "high," but these effects were unrelated to relief from their pain symptoms. Results of their study, one of the first to examine the addictive...

Weight Management is Not Enough for Cannabinoid Type 1 (CB1) Receptor Antagonists to Become a Commercial Success

Huge clinical development program of first-in-class CB1 antagonist rimonabant to show benefits beyond weight reduction and avoid image as life-style drug BARCELONA, Spain | March 08, 2007 | The Business Intelligence firm La Merie S.L. reported today that Sanofi-Aventis’ first-in-class CB1 ...

CeNeRx BioPharma Obtains Rights to Novel Drug Candidate for Prevention and Treatment of Neurodegeneration Disorders

...ntion and treatment of neuropathies and neurodegenerative disorders; a series of novel compounds for anxiety and depression; and a series of selective cannabinoid compounds that have recently completed successful preclinical proof-of-concept studies for the treatment of pain, glaucoma and spasticity. More infor...

Pharmos Issues Business Update on Dextofisopam Trial and Financing

...ndpoint of adequate relief (n=141, p=0.033). The Company also has a proprietary technology platform focusing on discovery and development of synthetic cannabinoid compounds with a focus on CB2 receptor selective agonists. Various CB2-selective compounds from Pharmos' pipeline have completed preclinical studies t...

Advances in Science and Treatment of Pain Presented at 25th Annual American Academy of Pain Medicine Meeting January 28 - 31, 2009

...ent Jan. 29 from 3:30-5 PM and Jan. 30 from 9-10 AM Calcium Channel Blockers Compared for Neuropathic Pain, Poster 181 Addictive Qualities of cannabinoid Medication, Poster 193 Tramadol Outcomes, Poster 197 Safety, Tolerability and Effectiveness of Duloxetine for Fibromyalgia, Poster 204 ...

Pharmos Announces Clinical Results from Phase 2a Trial of Topical Diclofenac NanoEmulsion Cream

...ndpoint of adequate relief (n=141, p=0.033). The Company also has a proprietary technology platform focusing on discovery and development of synthetic cannabinoid compounds with a focus on CB2 receptor selective agonists. Various CB2-selective compounds from Pharmos' pipeline have completed preclinical studies t...

CeNeRx BioPharma Initiates Phase II Clinical Trial of Its Novel Antidepressant Agent Tyrima(TM)

...advantages over current agents for depression and are expected to have a good safety profile. The company is also developing its pipeline of selective cannabinoid compounds that have recently completed successful preclinical proof-of-concept studies for the treatment of pain, glaucoma and spasticity. More inform...

CeNeRx BioPharma Finalizes Plans to Initiate Phase II Trials for Its Novel Antidepressant Agent Tyrima(TM) Using Innovative Brain Imaging Study

...advantages over current agents for depression and are expected to have a good safety profile. The company is also developing its pipeline of selective cannabinoid compounds that have recently completed successful preclinical proof-of-concept studies for the treatment of pain, glaucoma and obesity. More informati...

CeNeRx BioPharma Announces Successful Completion of Phase l Clinical Program for Novel Antidepressant Agent Tyrima(TM)

...ver current agents for depression and are expected to have a good safety profile. The company is also developing its preclinical pipeline of selective cannabinoid compounds for the treatment of pain, glaucoma and obesity. More information about CeNeRx BioPharma can be found at http://www.cenerx.com . Contac...
Cannabinoid in Medical Definition

Depolarization-induced suppression of inhibition

...to the demonstration that DSI was dependent on the cannabinoid CB1 receptor function, there was no way of produ...l three demonstrated heavy involvement of the CB1 cannabinoid receptor in DSI, suggesting that the endocannabi...re the brain's mediators of DSI. They showed that cannabinoid receptor agonists, drugs that mimic the actions o...
Cannabinoid in Medical Dictionary

Gliomas

...ades that reflect the degree of malignancy. ... Cannabinoids as a potential new drug therapy for the treatment of gliomas . ... Expression of cannabinoid receptors and neurotrophins in human gliomas . ... Find out how malignant gliomas are graded and how the grade affects treatment and prognosi...
Cannabinoid in Biological News

Scripps research team defines new painkilling chemical pathway

...ills pain by activating a set of proteins known as cannabinoid receptors, which can also regulate appetite, infla...ylglycerol (2-AG). These natural components of the cannabinoid system remain the focus of intense efforts to deve...but also induced other effects associated with the cannabinoid receptors, namely hypothermia and decreased moveme...

LSUHSC research reports new method to protect brain cells from diseases like Alzheimer's

...ving COX-2 inhibitors has led to their recent withdrawal from the market and limits on their usages. Our research has shown that the use of endogenous cannabinoid 2-AG may avoid such side effects. Therefore, elevation of endogenous 2-AG levels by facilitating its production, inhibiting its decomposition, or dire...

Medicines derived from cannabis: a review of adverse events

...r cannibinoids, are available for medical purposes in Canada. As the use of cannabinoid medications increases, so do concerns about their potential to cause "adver...was based on the adverse events reported in 31 separate clinical studies of cannabinoid medications conducted between 1966 and 2007. Adverse events were categorize...

Study finds possible connection between marijuana abuse and stroke or heart attacks

... to impaired learning and memory. The active chemical in MJ called delta-9-tetrahyrdocannabinol (THC) is believed to exert these effects by binding to cannabinoid (CB) receptors located on several cell types in various organs. Scientists have found CB receptors in many organs including the brain, heart, liver, ...

Opium and marijuana research go underground

... research will identify novel genes for use in the metabolic engineering of opium poppy to accumulate high-value pharmaceutical alkaloids and to block cannabinoid production in cannabis. The latter will allow for a safe, legal, made-in-Canada cannabis crop that will have virtually none of the mind-altering chemi...

The endocannabinoids: Functional roles and therapeutic opportunities

...ell known marijuana effects. It was assumed that a cannabinoid receptor is not formed for the sake of a plant con...utative 'signaling' constituents together with the cannabinoid receptors are part of a new biochemical system in ...r after TBI. The endocannabinoids act via specific cannabinoid receptors, of which the CB1 receptors are most abu...

'Conversation stoppers' fight deadly bacterial infections

...ethanolamines (NAEs), which include the endogenous cannabinoid ("endocannabinoid") anandamide. The high activity ...edient D9-tetrahydrocannabinol (THC) in marijuana. cannabinoid receptors were first discovered in 1988; the first... Other research has shown that the endogenous cannabinoid system helps control food intake, among other crit...

Nanotechnology propels advances in regenerative medicine research

...ethanolamines (NAEs), which include the endogenous cannabinoid ("endocannabinoid") anandamide. The high activity ...edient D9-tetrahydrocannabinol (THC) in marijuana. cannabinoid receptors were first discovered in 1988; the first... Other research has shown that the endogenous cannabinoid system helps control food intake, among other crit...

Brown seaweed contains promising fat fighter, weight reducer

...ethanolamines (NAEs), which include the endogenous cannabinoid ("endocannabinoid") anandamide. The high activity ...edient D9-tetrahydrocannabinol (THC) in marijuana. cannabinoid receptors were first discovered in 1988; the first... Other research has shown that the endogenous cannabinoid system helps control food intake, among other crit...

Study shows enzyme builds neurotransmitters via newly discovered pathway

...ethanolamines (NAEs), which include the endogenous cannabinoid ("endocannabinoid") anandamide. The high activity ...edient D9-tetrahydrocannabinol (THC) in marijuana. cannabinoid receptors were first discovered in 1988; the first... Other research has shown that the endogenous cannabinoid system helps control food intake, among other crit...
Cannabinoid in Biological Technology

CeNeRx BioPharma Awarded New Patent for its Innovative Compounds That Selectively Target Peripheral Cannabinoid Receptors

--By Avoiding the CNS, These Compounds May Be Free of the Side Effects Associated with Traditional Cannabinoid Compounds-- RESEARCH TRIANGLE PARK, N.C., April 1 /PRNewswire/ -- CeNeRx BioPharma, Inc., a clinical stage company developing and commercializing innovative treatments for diseases o...

Dynamic Outlines Initial Target Markets for Pharmaceutical Cannabinoid Products

PALM SPRINGS, Calif., Dec. 5 /PRNewswire-FirstCall/ -- Dynamic Alert Limited (OTC Bulletin Board: DYMC) is pleased to announce that it has now identified its target markets for its pharmaceutical product line-up. The modalities will include a lozenge with some capacity for enhancing rapid onset th...

Pharmos Corporation Reports 2008 Fourth Quarter Results

...ndpoint of adequate relief (n=141, p=0.033). The Company also has a proprietary technology platform focusing on discovery and development of synthetic cannabinoid compounds with a focus on CB2 receptor selective agonists. Various CB2-selective compounds from Pharmos' pipeline have completed preclinical studies t...

Pharmos Announces Agreement to Sell Certain CB2 Selective Agonists

...ndpoint of adequate relief (n=141, p=0.033). The Company also has a proprietary technology platform focusing on discovery and development of synthetic cannabinoid compounds with a focus on CB2 receptor selective agonists. Various CB2-selective compounds from Pharmos' pipeline have completed preclinical studies t...

CeNeRx BioPharma Completes $15 Million Series B Financing

...Novel Antidepressant Tyrima(TM) and Advancement of cannabinoid Compounds - RESEARCH TRIANGLE PARK, N.C., Oct. 1...DD), to further characterize its novel preclinical cannabinoid pipeline and potentially to acquire additional dev...mpany is also developing its pipeline of selective cannabinoid compounds that have recently completed successful ...

US Neuropathic Pain Market Value Doubles to $5 Billion by 2018

...NP marketing approval: lacosamide (Schwarz Pharma), milnacipran (Forest Laboratories/Cypress Bioscience), transdermal capsaicin (NeurogesX) and a dual cannabinoid receptor agonist (GW/Bayer), and fentanyl buccal (Cephalon). Eighteen drugs are in Phase III development in the US including two GABA receptor agonist...

Pharmos Corporation to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference

...patients suffering from osteoarthritic knee pain. The Company's core proprietary technology platform focuses on discovery and development of synthetic cannabinoid compounds, especially CB2 receptor-selective (CB2-selective) agonists. PRS-639,058, the leading CB2-selective agonist, has demonstrated promising prec...

Pharmos Corporation Reports 2008 First Quarter Results

...patients suffering from osteoarthritic knee pain. The Company's core proprietary technology platform focuses on discovery and development of synthetic cannabinoid compounds, especially CB2 receptor-selective (CB2-selective) agonists. PRS-639,058, the leading CB2-selective agonist, has demonstrated promising prec...

Pharmos Corporation to Present at the 2007 RBC Capital Markets Healthcare Conference

...nt for pain in patients with knee osteoarthritis. The Company's core proprietary technology platform focuses on discovery and development of synthetic cannabinoid compounds, especially CB2 receptor-selective (CB2-selective) agonists. PRS-639,058, the leading CB2-selective agonist, has demonstrated promising prec...

Pharmos Corporation Reports 2007 Third Quarter Results

...nt for pain in patients with knee osteoarthritis. The Company's core proprietary technology platform focuses on discovery and development of synthetic cannabinoid compounds, especially CB2 receptor-selective (CB2-selective) agonists. PRS-639,058, the leading CB2-selective agonist, has demonstrated promising prec...
Other Tags
(Date:12/20/2014)... Twin Cities DI Day is recognized as the premier ... financial professionals come together each year to hear up ... to protect their clients and to be inspired by ... of disability. , On September 23rd, 2014, financial professionals ... The 13th Annual Twin Cities DI Day where they ...
(Date:12/19/2014)... 2014 Sweetdressy.com , a leading ... its newest selection of cheap prom dresses for ladies ... in the world and clients can buy these dresses ... prom dresses feature cool cuts and delicate craftsmanship, and ... the middle-end market. Discount shipping costs are available for ...
(Date:12/19/2014)... (PRWEB) December 19, 2014 SuperCloset raises ... SuperClone Rooms. SuperCloset continues to offer indoor growers the ... one of the new SuperClone Rooms with the award ... and turnkey indoor hydroponic grow room setup. , The ... world, SuperCloset’s SuperPonic SuperCloner 50 . ...
(Date:12/19/2014)... 2014 The print component of Vision ... subscription of the Toronto Star, with a circulation of ... The digital component is distributed nationally through a vast ... news sites and partner outlets. To explore the digital ... The publication features an exclusive interview with Mark ...
(Date:12/19/2014)... FRIDAY, Dec. 19, 2014 (HealthDay News) -- Injectable drug ... double the suicide attempt rate of other substance users, ... use is associated with the risk of suicide attempt ... the University of Montreal, said in a university news ... users. We wanted to know who among substance users ...
Breaking Medicine News(10 mins):Health News:The 13th Annual Twin Cities DI Day Now On Video 2Health News:The 13th Annual Twin Cities DI Day Now On Video 3Health News:Cheap Prom Dresses Online Now at Sweetdressy.com 2Health News:SuperCloset Continues to Innovate with New Complete Indoor Grow Room Packages, The SuperClone Rooms are the Newest Addition to the Award Winning SuperRoom Lineup 2Health News:Mark DeMontis, Founder of Courage Canada, shares his passion for bringing hockey to those affected by blindness in Mediaplanet’s “Vision and Hearing” campaign 2Health News:Cocaine, Amphetamines May Up Injection Drug Users' Suicide Risk 2
(Date:11/21/2014)... , November 18, 2014 According ... Market by Systems (Video, RFID, Access Control, Intrusion Detection, ... Hotels, Banks, Government), Component Service Geography - Global Forecasts ... Market is projected to be around $25 Billion in ... 2020, growing at a CAGR of 8.69%. ...
(Date:11/21/2014)... JOSE, Calif. , Nov. 20, 2014   ... global leader in microcontroller (MCU) and touch technology solutions, ... digital temperature sensors with the widest V cc ... delivers higher temperature accuracy and faster I 2 C ... registers and serial EEPROM memory making them ideal for ...
(Date:11/18/2014)... 18, 2014   EyeLock Inc. , a ... MorphoTrust USA (Safran), a leading U.S. ... a strategic partnership to offer comprehensive biometric identity ... (MVA), airport screening and financial services markets. ... serves consumers through a nationwide network of 1,100 ...
Breaking Biology News(10 mins):Industrial Security Systems Market Worth $38 Billion by 2020 2Industrial Security Systems Market Worth $38 Billion by 2020 3Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 2Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 3Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 4EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 2EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 3
Other Contents